CERO THERAPEUTICS HOLDINGS, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Chris Ehrlich and Andrew Kucharchuk his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Chris Ehrlich | Chairman and Chief Executive Officer and Director | April 15, 2025 |
| Chris Ehrlich | (Principal Executive Officer) | |
| /s/ Andrew Kucharchuk | Chief Financial Officer | April 15, 2025 |
| Andrew Kucharchuk | (Principal Financial and Accounting Officer) | |
| /s/ Brian Atwood | Director | April 15, 2025 |
| Brian Atwood | ||
| /s/ Michael Byrnes | Director | April 15, 2025 |
| Michael Byrnes | ||
| /s/ Kathleen LaPorte | Director | April 15, 2025 |
| Kathleen LaPorte | ||
| /s/ Shami Patel | Director | April 15, 2025 |
| Shami Patel | ||
| /s/ Lindsey Rolfe | Director | April 15, 2025 |
| Lindsey Rolfe | ||
**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 392) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 (Successor) and December 31, 2023 (Predecessor) | F-3 |
| Consolidated Statements of Operations for the periods from January 1, 2024 to February 13, 2024 (Predecessor) and February 14, 2024 to December 31, 2024 (Successor) and for the year ended December 31, 2023 (Predecessor) | F-4 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the periods from January 1, 2024 to February 13, 2024 (Predecessor) and February 14, 2024 to December 31, 2024 (Successor) and for the year ended December 31, 2023 (Predecessor) | F-5 |
| Consolidated Statements of Cash Flows for the periods from January 1, 2024 to February 13, 2024 (Predecessor) and February 14, 2024 to December 31, 2024 (Successor) and for the year ended December 31, 2023 (Predecessor) | F-6 |
| Notes to Consolidated Financial Statements | F-7 to F-33 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.